OCC

2.63%

39.0¢ orthocell limited

Movement at the Station, page-59

First 59 Last

Share
Profile

Follow
Stockcount

4,283 Posts.

815

03/12/22

18:04

Post #: 65135218
Share

Originally posted by Merchantech: ↑

In regards to OrthoATI and partnering with J&J or someone else.
I don't believe they will engage partners till they have a clear pathway with the FDA and have an approved IND ( Study) which would enable them to discuss better terms if they chose to partner with the product.

Below was from a previous presentation.

US addressable market
Initial market sizing undertaken by Orthocell suggests that Ortho-ATI™ could be applicable to >480,000 rotator
cuff patients per year in the US alone, which equates to a market opportunity of approximately US$4-5 billion1
.
Ongoing work by Orthocell aims to also assess the savings to the health system that may be delivered by
OrthoATI™ when accounting for more effective pain relief and return of function, return to work and
avoidance of surgical costs. Ortho-ATI™ can be used in both pre-surgical and post-surgical applications, not
only in treating rotator cuff injuries, but many other tendon injuries and is at the forefront of a significant and
increasing market opportunity.
Next Steps
The Orthocell team was responsible for the initial development of a similar cell therapy product for the
regeneration of cartilage (known as MACI) which is now being commercialised by US company Vericel, which
currently generates more than $120 million in sales and is only used to treat one target joint in the body.
Vericel currently has a market capitalisation of approximately $1.2 billion.
1 Internal Orthocell modelling based on published epidemiology data and assuming target pricing for a subset of the rotator cuff injury segment.

Orthocell is in a strong position to advance its US commercialisation strategy to deliver the first injectable cell
therapy in orthopaedics for the treatment of chronic tendon injuries.2
The results of this study demonstrate that OrthoATI™ is more effective than steroid injections for treatment of rotator cuff tendinopathy with
intrasubstance tendon tear. The Company continues to progressits US plans with the evaluation of technology
transfer options, FDA engagement and commercial preparation activities to prepare OrthoATI™ for a
randomised controlled study under FDA supervision

Expand

The resistance to this from all the surgeons that operate on rotator cuffs and ACLs would be massive.

How do you get around that one ?

OCC Price at posting: 46.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

GNX

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

FG1

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Talking Australia's very competitive property landscape: Realty Talks

LKE

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

IMR

Imricor raises $35M to pursue growth and expansion into Australia and NZ

MCT

Metalicity looking for offers on Admiral Bay zinc project

There are more pages in this discussion • 13 more messages in this thread...

First 59 Last

Add OCC (ASX) to my watchlist

(20min delay)
Last 39.0¢		Change 0.010(2.63%)		Mkt cap ! $81.63M

Open	High	Low	Value	Volume
37.5¢	39.0¢	37.5¢	$49.66K	129.0K

Buyers (Bids)

No.	Vol.	Price($)
3	20305	37.5¢

Sellers (Offers)

Price($)	Vol.	No.
39.0¢	77938	2

View Market Depth

No.	Vol.	Price($)
3	20305	0.375
6	58439	0.370
3	106401	0.365
7	80957	0.360
8	68054	0.355

Price($)	Vol.	No.
0.390	77938	2
0.395	6205	2
0.400	145274	6
0.405	11143	1
0.410	119177	7

Last trade - 16.10pm 19/07/2024 (20 minute delay)

OCC (ASX) Chart

Movement at the Station, page-59

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Talking Australia's very competitive property landscape: Realty Talks

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Metalicity looking for offers on Admiral Bay zinc project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Movement at the Station, page-59

Top Stories

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Talking Australia's very competitive property landscape: Realty Talks

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Metalicity looking for offers on Admiral Bay zinc project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News